Immuron Limited Announces Planned IND Submission to FDA for IMM-529 Targeting C. difficile Infection, Paving Way for Phase 2 Clinical Trials
I'm PortAI, I can summarize articles.
Immuron Limited (ASX: IMC; NASDAQ: IMRN) has announced plans to submit an Investigational New Drug (IND) application to the FDA for its candidate IMM-529, targeting C. difficile infection, by mid-October 2025. This submission will allow the company to start a Phase 2 clinical program. Additionally, pre-clinical studies for IMM-986, aimed at treating Vancomycin-resistant Enterococci, are expected to be completed by the end of 2025. The company confirmed that its Travelan® product is unaffected by new U.S. pharmaceutical tariffs.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments